GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (STU:AB3A) » Definitions » E10

Sarepta Therapeutics (STU:AB3A) E10 : €-5.70 (As of Sep. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Sarepta Therapeutics E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Sarepta Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was €0.306. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-5.70 for the trailing ten years ended in Sep. 2024.

During the past 3 years, the average E10 Growth Rate was -10.70% per year. During the past 5 years, the average E10 Growth Rate was -13.80% per year. During the past 10 years, the average E10 Growth Rate was -9.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Sarepta Therapeutics was 11.80% per year. The lowest was -18.60% per year. And the median was -3.00% per year.

As of today (2025-03-03), Sarepta Therapeutics's current stock price is €98.74. Sarepta Therapeutics's E10 for the quarter that ended in Sep. 2024 was €-5.70. Sarepta Therapeutics's Shiller PE Ratio of today is .


Sarepta Therapeutics E10 Historical Data

The historical data trend for Sarepta Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics E10 Chart

Sarepta Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.96 -5.07 -5.68 -5.99 -

Sarepta Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.99 -6.05 -6.02 -5.70 -

Competitive Comparison of Sarepta Therapeutics's E10

For the Biotechnology subindustry, Sarepta Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Shiller PE Ratio falls into.



Sarepta Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sarepta Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.306/133.0289*133.0289
=0.306

Current CPI (Sep. 2024) = 133.0289.

Sarepta Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201412 -0.876 99.070 -1.176
201503 -1.377 99.621 -1.839
201506 -0.900 100.684 -1.189
201509 -1.114 100.392 -1.476
201512 -1.322 99.792 -1.762
201603 -1.176 100.470 -1.557
201606 -1.202 101.688 -1.572
201609 -1.051 101.861 -1.373
201612 -1.536 101.863 -2.006
201703 1.402 102.862 1.813
201706 -1.024 103.349 -1.318
201709 -0.654 104.136 -0.835
201712 -0.313 104.011 -0.400
201803 -0.446 105.290 -0.564
201806 -1.430 106.317 -1.789
201809 -0.986 106.507 -1.232
201812 -1.804 105.998 -2.264
201903 -0.947 107.251 -1.175
201906 -3.310 108.070 -4.074
201909 -1.544 108.329 -1.896
201912 -2.853 108.420 -3.501
202003 -0.208 108.902 -0.254
202006 -1.714 108.767 -2.096
202009 -2.123 109.815 -2.572
202012 -1.981 109.897 -2.398
202103 -1.764 111.754 -2.100
202106 -0.847 114.631 -0.983
202109 -0.510 115.734 -0.586
202112 -1.266 117.630 -1.432
202203 -1.090 121.301 -1.195
202206 -2.507 125.017 -2.668
202209 -2.969 125.227 -3.154
202212 -1.171 125.222 -1.244
202303 -5.473 127.348 -5.717
202306 -0.249 128.729 -0.257
202309 -0.431 129.860 -0.442
202312 0.697 129.419 0.716
202403 0.340 131.776 0.343
202406 0.065 132.554 0.065
202409 0.306 133.029 0.306

Add all the adjusted EPS together and divide 10 will get our e10.


Sarepta Therapeutics  (STU:AB3A) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Sarepta Therapeutics E10 Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics Business Description

Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Sarepta Therapeutics Headlines

No Headlines